Feb 28, 2019
SCYNEXIS to Present Pre-clinical Data Supporting Prophylactic Use of Ibrexafungerp at Superbugs and Superdrugs 2019
Feb 07, 2019
The candidiasis drugs market will register a CAGR of almost 4% by 2023
Nov 13, 2018
SCYNEXIS Reports Third Quarter 2018 Financial Results and Provides Company Update
Nov 13, 2018
Amplyx Doses First Patient in Phase 2 Trial of APX001 in Patients with Candida Infection
Oct 23, 2018
BioGX Launches 5 new CE Mark IVD Tests, Expands Sexual Health Panels on the BD MAX(TM)
Oct 15, 2018
SCYNEXIS, Inc. Announces First Patient Dosed in Phase 3 Open-label Study Evaluating Oral Ibrexafungerp in Candida auris Infections (CARES)
May 24, 2018
SCYNEXIS to Present SCY-078 Data at ASM Microbe 2018
Apr 30, 2018
Amplyx Pharmaceuticals Demonstrates APX001 has Potent Activity Against Deadly Multidrug-Resistant Candida Species
Apr 20, 2018
FDA authorizes new use of test, first to identify the emerging pathogen Candida auris
Apr 05, 2018
Published Research Shows Ceragenin CSA-131's Potent Efficacy against Candida auris, a New Serious Global Health Threat
Mar 20, 2018
SCYNEXIS Presents Data at Superbugs and Superdrugs 2018
Nov 07, 2017
SCYNEXIS Reports Third Quarter 2017 Financial Results and Provides Company Update
Oct 09, 2017
Amplyx Pharmaceuticals Highlights Phase 1 APX001 Data at IDWeek 2017
Oct 06, 2017
Bruker Introduces Additional Key Products for Diagnosis and Susceptibility Testing of Invasive Fungal Diseases (IFD) into European Clinical Microbiology Markets
Aug 03, 2017
Candidiasis Therapeutics Pipeline Analysis, 2017 - Approximately 22 Active Drug Candidates in Different Stages of Development